| Budget Amount *help |
¥25,220,000 (Direct Cost: ¥19,400,000、Indirect Cost: ¥5,820,000)
Fiscal Year 2015: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2014: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2013: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2012: ¥15,990,000 (Direct Cost: ¥12,300,000、Indirect Cost: ¥3,690,000)
|
|---|
| Outline of Final Research Achievements |
Research for developing radioprotectors is extremely important as one of a few methods to reduce a radiation risk. In addition, the damage of normal tissues during radiation therapy produces a dose-limiting toxicity (tolerance dose). Therefore, the development of the radioprotectors that raise the tolerance dose is expected. As radioprotective usefulness by regulating p53, some chemical p53 regulators would be expected to selectively prevent the damage of normal tissues during radiotherapy for p53-deficient tumors. In this study, I attempted to discover compounds that target the zinc-binding site in p53, and found several radioprotectors that regulate p53.
|
